Five birds, one stone: Neutralization of α-hemolysin and 4 bi-component leukocidins of Staphylococcus aureus with a single human monoclonal antibody

mAbs

Volumn 7, Issue 1, 2015, Pages 243-254

  Rouha, Harald ^a   Badarau, Adriana ^a   Visram, Zehra C ^a   Battles, Michael B ^b,e   Prinz, Bianka ^b   Magyarics, Zoltán ^a   Nagy, Gábor ^a   Mirkina, Irina ^a   Stulik, Lukas ^a   Zerbs, Manuel ^a   Jägerhofer, Michaela ^a   Maierhofer, Barbara ^a   Teubenbacher, Astrid ^a   Dolezilkova, Ivana ^a   Gross, Karin ^a   Banerjee, Srijib ^a,f   Zauner, Gerhild ^a   Malafa, Stefan ^a   Zmajkovic, Jakub ^a   Maier, Sabine ^a   Mabry, Robert ^b,g   Krauland, Eric ^b   Dane Wittrup, K ^b,c   Gerngross, Tillman U ^a,b,d   Nagy, Eszter ^a   more..

^a Arsanis Biosciences   (Austria)

^b Adimab LLC   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d DARTMOUTH COLLEGE   (United States)

^e DARTMOUTH MEDICAL SCHOOL   (United States)

^f BOEHRINGER INGELHEIM RCV GMBH AND CO KG   (Austria)

^g Jounce Therapeutics   (United States)

Author keywords

Engineered cross reactivity; Exotoxins; In vitro potency; In vivo efficacy; Monoclonal antibody; Staphylococcus aureus; Toxin neutralization

Indexed keywords

ALPHA HEMOLYSIN; CROSS REACTING ANTIBODY; HUMAN MONOCLONAL ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; LEUKOCIDIN; LEUKOCIDIN ED; LEUKOCIDIN GH; LEUKOCIDIN SF; LINEZOLID; MONOCLONAL ANTIBODY HLAF; NEUTRALIZING ANTIBODY; PANTON VALENTINE LEUKOCIDIN; UNCLASSIFIED DRUG; BACTERIAL PROTEIN; BACTERIUM ANTIBODY; HEMOLYSIN; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY ISOLATION; ANTIBODY LIBRARY; ANTIGEN BINDING; ARTICLE; BACTERIAL VIRULENCE; BINDING AFFINITY; BINDING SITE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CROSS REACTION; CRYSTAL STRUCTURE; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MOUSE; NONHUMAN; SINGLE DRUG DOSE; STAPHYLOCOCCAL BACTEREMIA; STAPHYLOCOCCAL PNEUMONIA; ANIMAL; ANTIBODY SPECIFICITY; CELL LINE; CHEMISTRY; IMMUNOLOGY; RABBIT; STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; BACTERIAL PROTEINS; CELL LINE; HEMOLYSIN PROTEINS; HUMANS; IMMUNOGLOBULIN G; LEUKOCIDINS; RABBITS; STAPHYLOCOCCUS AUREUS;

EID: 84921376947     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/19420862.2014.985132     Document Type: Article

References (52)

1. Chambers HF, Deleo FR. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol 2009; 7:629-641; PMID:19680247; http://dx.doi.org/10.1038/nrmicro2200
2. Jansen KU, Girgenti DQ, Scully IL, Anderson AS. Vaccine review: "Staphyloccocus aureus vaccines: problems and prospects". Vaccine 2013; 31:2723-2730; PMID:23624095; http://dx.doi.org/10.1016/j.vaccine.2013.04.002
3. Oleksiewicz MB, Nagy G, Nagy E. Anti-bacterial monoclonal antibodies: back to the future? Arch Biochem Biophys 2012; 526:124-131; PMID:22705202; http://dx.doi.org/10.1016/j.abb.2012.06.001
4. Cheung GY, Otto M. The potential use of toxin antibodies as a strategy for controlling acute Staphylococcus aureus infections. Expert Opin Ther Targets 2012; 16:601-612; PMID:22530584; http://dx.doi.org/10.1517/14728222.2012.682573
5. Aman MJ, Adhikari RP. Staphylococcal bicomponent pore-forming toxins: targets for prophylaxis and immunotherapy. Toxins (Basel) 2014; 6: 950-972; PMID:24599233; http://dx.doi.org/10.3390/toxins6030950
6. Berube BJ, BubeckWardenburg J. Staphylococcus aureus alpha-toxin: nearly a century of intrigue. Toxins (Basel) 2013; 5:1140-1166; PMID:23888516; http://dx.doi.org/10.3390/toxins5061140
7. Bubeck Wardenburg J, Schneewind O. Vaccine protection against Staphylococcus aureus pneumonia. J Exp Med 2008; 205:287-294; PMID:18268041; http://dx.doi.org/10.1084/jem.20072208
8. Kennedy AD, Bubeck Wardenburg J, Gardner DJ, Long D, Whitney AR, Braughton KR, Schneewind O, DeLeo FR. Targeting of alpha-hemolysin by active or passive immunization decreases severity of USA300 skin infection in a mouse model. J Infect Dis 2010; 202:1050-1058; PMID:20726702; http://dx.doi.org/10.1086/656043
9. Adhikari RP, Karauzum H, Sarwar J, Abaandou L, Mahmoudieh M, Boroun AR, Vu H, Nguyen T, Devi VS, Shulenin S, et al. Novel structurally designed vaccine for S. aureus alpha-hemolysin: protection against bacteremia and pneumonia. PLoS One 2012; 7: e38567; PMID:22701668; http://dx.doi.org/10.1371/journal.pone.0038567
10. Hua L, Hilliard JJ, Shi Y, Tkaczyk C, Cheng LI, Yu X, Datta V, Ren S, Feng H, Zinsou R, et al. Assessment of an anti-alpha-toxin monoclonal antibody for prevention and treatment of Staphylococcus aureus-induced pneumonia. Antimicrob Agents Chemother 2014; 58:1108-1117; PMID:24295977; http://dx.doi.org/10.1128/AAC.02190-13
11. Foletti D, Strop P, Shaughnessy L, Hasa-Moreno A, Casas MG, Russell M, Bee C, Wu S, Pham A, Zeng Z, et al. Mechanism of action and in vivo efficacy of a human-derived antibody against Staphylococcus aureus alpha-hemolysin. J Mol Biol 2013; 425:1641-1654; PMID:23416200; http://dx.doi.org/10.1016/j.jmb.2013.02.008
12. Vandenesch F, Lina G, Henry T. Staphylococcus aureus hemolysins, bi-component leukocidins, and cytolytic peptides: a redundant arsenal of membrane-damaging virulence factors? Front Cell Infect Microbiol 2012; 2:12; PMID:22919604; http://dx.doi.org/10.3389/fcimb.2012.00012
13. Alonzo F 3rd, Torres VJ. The bicomponent pore-forming leucocidins of Staphylococcus aureus. Microbiol Mol Biol Rev 2014; 78: 199-230; PMID:24847020; http://dx.doi.org/10.1128/MMBR.00055-13
14. DuMont AL, Torres VJ. Cell targeting by the Staphylococcus aureus pore-forming toxins: it's not just about lipids. Trends Microbiol 2014; 22:21-27; PMID:24231517; http://dx.doi.org/10.1016/j.tim.2013.10.004
15. DeLeo FR, Diep BA, Otto M. Host defense and pathogenesis in Staphylococcus aureus infections. Infect Dis Clin North Am 2009; 23:17-34; PMID:19135914; http://dx.doi.org/10.1016/j.idc.2008.10.003
16. Alonzo F III, Kozhaya L, Rawlings SA, Reyes-Robles T, DuMont AL, Myszka DG, Landau NR, Unutmaz D, Torres VJ. CCR5 is a receptor for Staphylococcus aureus leukotoxin ED. Nature 2013; 493:51-55; PMID:23235831; http://dx.doi.org/10.1038/nature11724
17. Malachowa N, Kobayashi SD, Braughton KR, Whitney AR, Parnell MJ, Gardner DJ, Deleo FR. Staphylococcus aureus leukotoxin GH promotes inflammation. J Infect Dis 2012; 206:1185-1193; PMID:22872735; http://dx.doi.org/10.1093/infdis/jis495
18. Adhikari RP, Ajao AO, Aman MJ, Karauzum H, Sarwar J, Lydecker AD, Johnson JK, Nguyen C, Chen WH, Roghmann MC. Lower antibody levels to Staphylococcus aureus exotoxins are associated with sepsis in hospitalized adults with invasive S. aureus infections. J Infect Dis 2012; 206:915-923; PMID:22807524; http://dx.doi.org/10.1093/infdis/jis462
19. Fritz SA, Tiemann KM, Hogan PG, Epplin EK, Rodriguez M, Al-ZubeidiDN, BubeckWardenburg J, Hunstad DA. A serologic correlate of protective immunity against community-onset Staphylococcus aureus infection. Clin Infect Dis 2013; 56:1554-1561; PMID:23446627; http://dx.doi.org/10.1093/cid/cit123
20. Song L, Hobaugh MR, Shustak C, Cheley S, Bayley H, Gouaux JE. Structure of staphylococcal alpha-hemolysin, a heptameric transmembrane pore. Science 1996; 274:1859-1866; PMID:8943190; http://dx.doi.org/10.1126/science.274.5294.1859
21. Bhakdi S, Tranum-Jensen J. Alpha-toxin of Staphylococcus aureus. Microbiol Rev 1991; 55:733-751; PMID:1779933
22. Kaneko J, Kamio Y. Bacterial two-component and hetero-heptameric pore-forming cytolytic toxins: structures, pore-forming mechanism, and organization of the genes. Biosci Biotechnol Biochem 2004; 68:981-1003; PMID:15170101; http://dx.doi.org/10.1271/bbb.68.981
23. Guillet V, Roblin P, Werner S, Coraiola M, Menestrina G, Monteil H, Prevost G, Mourey L. Crystal structure of leucotoxin S component: new insight into the staphylococcal beta-barrel pore-forming toxins. J Biol Chem 2004; 279:41028-41037; PMID:15262988; http://dx.doi.org/10.1074/jbc.M406904200
24. Yamashita K, Kawai Y, Tanaka Y, Hirano N, Kaneko J, Tomita N, Ohta M, Kamio Y, Yao M, Tanaka I. Crystal structure of the octameric pore of staphylococcal gamma-hemolysin reveals the beta-barrel pore formation mechanism by two components. Proc Natl Acad Sci USA 2011; 108:17314-17319; http://dx.doi.org/10.1073/pnas.1110402108
25. Boder ET, Wittrup KD. Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol 1997; 15:553-557; PMID:9181578; http://dx.doi.org/10.1038/nbt0697-553
26. Blaise L, Wehnert A, Steukers MP, van den Beucken T, Hoogenboom HR, Hufton SE. Construction and diversification of yeast cell surface displayed libraries by yeast mating: application to the affinity maturation of Fab antibody fragments. Gene 2004; 342:211-218; PMID:15527980; http://dx.doi.org/10.1016/j.gene.2004.08.014
27. Rakestraw JA, Aird D, Aha PM, Baynes BM, Lipovsek D. Secretion-and-capture cell-surface display for selection of target-binding proteins. Protein Eng Des Sel 2011; 24:525-530; PMID:21402751; http://dx.doi.org/10.1093/protein/gzr008
28. Vasquez M, Feldhaus M, Gerngross TU, Wittrup KD, inventors; Adimab Inc, assignee. Rationally designed, synthetic antibody libraries and uses therefor. World patent WO2009036379. 2009 March 19.
29. Xu Y, Roach W, Sun T, Jain T, Prinz B, Yu TY, Torrey J, Thomas J, Bobrowicz P, Vasquez M, et al. Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: a FACS-based, high-throughput selection and analytical tool. Protein Eng Des Sel 2013; 26:663-670; PMID:24046438; http://dx.doi.org/10.1093/protein/gzt047
30. Rudolf M, Koch H, inventors; Kenta Biotech AG, assignee. Human monoclonal antibody against S. aureus derived alpha-toxin and its use in treating or preventing abscess formation patent. World patent WO2011018208 2011 February 17.
31. Sellman B, Tkaczyk C, Hua L, Chowdhury P, Varkey R, Damschroder M, Peng L, Oganesyan V, Hilliard JJ, inventors; MedImmune LLC, assignee. Antibodies that specifically bind Staphylococcus aureus alpha toxin and methods of use patent. World patent WO2012109285. 2012 August 16.
32. Foletti DL, Chapparo Riggers JF, Glanville JEG, Shaughnessy LMB, Shelton DL, Strop P, Zhai W, inventors; Rinat Neuroscience Corp., assignee. Staphylococcus aureus specific antibodies and uses thereof. US patent US20130164308. 2013 June 27.
33. Oganesyan V, Peng L, Damschroder MM, Cheng L, Sadowska A, Tkaczyk C, Sellman BR, Wu H, Dall'Acqua WF. Mechanisms of neutralization of a human anti-alpha toxin antibody. J Biol Chem 2014; 289:29874-29880
34. Olson R, Nariya H, Yokota K, Kamio Y, Gouaux E.Crystal structure of staphylococcal LukF delineates conformational changes accompanying formation of a transmembrane channel. Nat Struct Biol 1999; 6:134-140;PMID:10048924; http://dx.doi.org/10.1038/5821
35. Pedelacq JD, Maveyraud L, Prevost G, Baba-Moussa L, Gonzalez A, Courcelle E, Shepard W, Monteil H, Samama JP, Mourey L. The structure of a Staphylococcus aureus leucocidin component (LukF-PV) reveals the fold of the water-soluble species of a family of transmembrane pore-forming toxins. Structure 1999; 7:277-287; PMID:10368297; http://dx.doi.org/10.1016/S0969-2126(99)80038-0
36. Valeva A, Hellmann N, Walev I, Strand D, Plate M, Boukhallouk F, Brack A, Hanada K, Decker H, Bhakdi S. Evidence that clustered phosphocholine head groups serve as sites for binding and assembly of an oligomeric protein pore. J Biol Chem 2006; 281:26014-26021; PMID:16829693; http://dx.doi.org/10.1074/jbc.M601960200
37. Potrich C, Bastiani H, Colin DA, Huck S, Prevost G, Dalla Serra M. The influence of membrane lipids in Staphylococcus aureus gamma-hemolysins pore formation. J Membr Biol 2009; 227:13-24; PMID:19067025; http://dx.doi.org/10.1007/s00232-008-9140-6
38. Monma N, Nguyen VT, Kaneko J, Higuchi H, Kamio Y. Essential residues, W177 and R198, of LukF for phospha-tidylcholine-binding and pore-formation by staphylococcal gamma-hemolysin on human erythrocytemembranes. J Biochem 2004; 136:427-431; PMID:15625310; http://dx.doi.org/10.1093/jb/mvh140
39. Maynard JA, Maassen CBM, Leppla SH, Brasky K, Patterson JL, Iverson BL, Georgiou G. Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity. Nat Biotechnol 2002; 20:597-601; PMID:12042864; http://dx.doi.org/10.1038/nbt0602-597
40. Tkaczyk C, Hua L, Varkey R, Shi Y, Dettinger L, Woods R, Barnes A, MacGill RS, Wilson S, Chowdhury P, et al. Identification of anti-alpha toxin monoclonal antibodies that reduce the severity of Staphylococcus aureus dermonecrosis and exhibit a correlation between affinity and potency. Clin Vaccine Immunol 2012; 19:377-385; PMID:22237895; http://dx.doi.org/10.1128/CVI.05589-11
41. Garcia-Rodriguez C, Geren IN, Lou J, Conrad F, Forsyth C, Wen W, Chakraborti S, Zao H, Manzanarez G, Smith TJ, Brown J, et al. Neutralizing human monoclonal antibodies binding multiple serotypes of botulinum neurotoxin. Protein Eng Des Sel 2011; 24:321-331; PMID:21149386; http://dx.doi.org/10.1093/protein/gzq111
42. Ragle BE, Bubeck Wardenburg J. Anti-alpha-hemolysin monoclonal antibodies mediate protection against Staphylococcus aureus pneumonia. Infect Immun 2009; 77:2712-2718; PMID:19380475; http://dx.doi.org/10.1128/IAI.00115-09
43. Malachowa N, Whitney AR, Kobayashi SD, Sturdevant DE, Kennedy AD, Braughton KR, Shabb DW, Diep BA, Chambers HF, Otto M, DeLeo FR. Global changes in Staphylococcus aureus gene expression in human blood. PLoS One 2011; 6:e18617; PMID:21525981; http://dx.doi.org/10.1371/journal.pone.0018617
44. Ishii K, Adachi T, Yasukawa J, Suzuki Y, Hamamoto H, Sekimizu K. Induction of virulence gene expression in Staphylococcus aureus by pulmonary surfactant. Infect Immun 2014; 82:1500-10; PMID:24452679; http://dx.doi.org/10.1128/IAI.01635-13
45. Diep BA, Chan L, Tattevin P, Kajikawa O, Martin TR, Basuino L, Mai TT, Marbach H, Braughton KR, Whitney AR, et al. Polymorphonuclear leukocytes mediate Staphylococcus aureus Panton-Valentine leukocidin-induced lung inflammation and injury. Proc. Natl. Acad. Sci. USA 2010; 107:5587-5592; http://dx.doi.org/10.1073/pnas.0912403107
46. Chen HY, Chen CC, Fang CS, Hsieh YT, Lin MH, Shu JC. Vancomycin activates sigma(B) in vancomycin-resistant Staphylococcus aureus resulting in the enhancement of cytotoxicity. PLoS One 2011; 6: e24472; PMID:21912698; http://dx.doi.org/10.1371/journal.pone.0024472
47. Pichereau S, Pantrangi M, Couet W, Badiou C, Lina G, Shukla SK, Rose WE. Simulated antibiotic exposures in an in vitro hollow-fiber infection model influence toxin gene expression and production in community-associated methicillin-resistant Staphylococcus aureus strain MW2. Antimicrob Agents Chemother 2012; 56:140-147; PMID:22064533; http://dx.doi.org/10.1128/AAC.05113-11
48. Rudkin JK, Laabei M, Edwards AM, Joo HS, Otto M, Lennon KL, O'Gara JP, Waterfield NR, Massey RC. Oxacillin alters the toxin expression profile of community-associated methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2014; 58:1100-1107; PMID:24295979; http://dx.doi.org/10.1128/AAC.01618-13
49. McNamara PJ, Lindsay JA, editor. Staphylococcus: Molecular Genetics, 1st ed., Genetic Manipulation of Staphylococcus aureus. Norfolk, UK: Caister Academic Press; 2008. 100-12 p.
50. Kato F, Sugai M. A simple method of markerless gene deletion in Staphylococcus aureus. J Microbiol Methods 2011; 87:76-81; PMID:21801759; http://dx.doi.org/10.1016/j.mimet.2011.07.010
51. Estep P, Reid F, Nauman C, Liu Y, Sun T, Sun J, Xu Y. High throughput solution-based measurement of antibody-antigen affinity and epitope binning. Mabs 2013; 5:270-278; PMID:23575269; http://dx.doi.org/10.4161/mabs.23049
52. Arnold K, Bordoli L, Kopp J, Schwede T. The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics 2006; 22:195-201; PMID:16301204; http://dx.doi.org/10.1093/bioinformatics/bti770